Heterologous prime-boost vaccination

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

Shiver, J. W., Fu, T., Chen, L., Casimiro, D. R., Davies, M.-E., Evans, R. K., Zhang, Z., Simon, A. J., Trigona, W. L., Dubey, S. A., et al. (2002) · Nature · doi:10.1038/415331a · Cited by 1,173

Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine

Amara, R. R. (2001) · Science · doi:10.1126/science.1058915 · Cited by 1,110

The prime-boost strategy: exciting prospects for improved vaccination

Ramshaw, I. A., & Ramsay, A. J. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01612-1 · Cited by 373

Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus.

Girard, M. P., Kiény, M. P., Pinter, A., Barré‐Sinoussi, F., Nara, P. L., Kolbe, H. V. J., Kusumi, K., Chaput, A., Reinhart, T. A., & Muchmore, E. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.2.542 · Cited by 353

Protection of Macaques Against SIV Infection by Subunit Vaccines of SIV Envelope Glycoprotein gp160

Hu, S.-L., Abrams, K., Barber, G. N., Moran, P. A., Zarling, J. M., Langlois, A. J., Kuller, L., Morton, W. R., & Benveniste, R. Ė. (1992) · Science · doi:10.1126/science.1531159 · Cited by 335

Enhanced T-Cell Immunogenicity and Protective Efficacy of a Human Immunodeficiency Virus Type 1 Vaccine Regimen Consisting of Consecutive Priming with DNA and Boosting with Recombinant Fowlpox Virus

Kent, S. J., Zhao, A., Best, S. J., Chandler, J. D., Boyle, D. B., & Ramshaw, I. A. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.10180-10188.1998 · Cited by 325

Effective Induction of Simian Immunodeficiency Virus-Specific Cytotoxic T Lymphocytes in Macaques by Using a Multiepitope Gene and DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccination Regimen

Hanke, T., Samuel, R. V., Blanchard, T. J., Neumann, V. C., Allen, T. M., Boyson, J. E., Sharpe, S. A., Cook, N. M., Smith, G. L., Watkins, D. I., et al. (1999) · Journal of Virology · doi:10.1128/jvi.73.9.7524-7532.1999 · Cited by 304

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses

Harari, A., Bart, P., Stöhr, W., Tapia, G., Garcia, M., Medjitna-Rais, E., Burnet, S., Cellerai, C., Erlwein, O. W., Barber, T., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071331 · Cited by 299

Priming for and induction of anti-poliovirus neutralizing antibodies by synthetic peptides

Emini, E. A., Jameson, B. A., & Wimmer, E. (1983) · Nature · doi:10.1038/304699a0 · Cited by 237

A group specific anamnestic immune reaction against HIV-1 induced by a candidate vaccine against AIDS

Zagury, D., Bernard, J., Cheynier, R., Desportes, I., Leonard, R., Fouchard, M., Réveil, B., Ittelé, D., Lurhuma, Z., Mbayo, K., et al. (1988) · Nature · doi:10.1038/332728a0 · Cited by 185

Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime–protein boost HIV-1 vaccine in healthy human volunteers

Wang, S., Kennedy, J. S., West, K., Montefiori, D. C., Coley, S., Lawrence, J., Shen, S., Green, S., Rothman, A. L., Ennis, F. A., et al. (2008) · Vaccine · doi:10.1016/j.vaccine.2007.12.024 · Cited by 180

A DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccine Encoding Thrombospondin-Related Adhesion Protein but Not Circumsporozoite Protein Partially Protects Healthy Malaria-Naive Adults against Plasmodium falciparum Sporozoite Challenge

Dunachie, S. J., Walther, M. R., Epstein, J., Keating, S. M., Berthoud, T. K., Andrews, L., Andersen, R. F., Bejon, P., Goonetilleke, N. P., Poulton, I. D., et al. (2006) · Infection and Immunity · doi:10.1128/iai.00590-06 · Cited by 164

Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit

Barnett, S. W. (1997) · Vaccine · doi:10.1016/s0264-410x(96)00264-2 · Cited by 146

Current progress of DNA vaccine studies in humans

Lu, S., Wang, S., & Grimes-Serrano, J. M. (2008) · Expert Review of Vaccines · doi:10.1586/14760584.7.2.175 · Cited by 143

Safety and Immunogenicity of an HIV Subtype B and E Prime‐Boost Vaccine Combination in HIV‐Negative Thai Adults

Nitayaphan, S., Pitisuttithum, P., Karnasuta, C., Eamsila, C., de Souza, M. S., Morgan, P., Polonis, V. R., Benenson, M. W., VanCott, T., Ratto‐Kim, S., et al. (2004) · The Journal of Infectious Diseases · doi:10.1086/422258 · Cited by 139

Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine

Amara, R. R., Villinger, F. J., Altman, J. D., Lydy, S. L., O’Neil, S. P., Staprans, S. I., Montefiori, D. C., Xu, Y., Herndon, J. G., Wyatt, L. S., et al. (2001) · Science · doi:10.1126/science.292.5514.69 · Cited by 133

Studies of the Neutralizing Activity and Avidity of Anti-Human Immunodeficiency Virus Type 1 Env Antibody Elicited by DNA Priming and Protein Boosting

Richmond, J. F. L., Lu, S., Santoro, J. C., Weng, J., Hu, S.-L., Montefiori, D. C., & Robinson, H. L. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.9092-9100.1998 · Cited by 124

Plasmid Chemokines and Colony-Stimulating Factors Enhance the Immunogenicity of DNA Priming-Viral Vector Boosting Human Immunodeficiency Virus Type 1 Vaccines

Barouch, D. H., McKay, P. F., Sumida, S. M., Santra, S., Jackson, S. S., Gorgone, D. A., Lifton, M. A., Chakrabarti, B. K., Xu, L., Nabel, G. J., et al. (2003) · Journal of Virology · doi:10.1128/jvi.77.16.8729-8735.2003 · Cited by 122

Evaluating the Immunogenicity of a Disulfide-Stabilized, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1

Beddows, S. A., Schülke, N., Kirschner, M. W., Barnes, K., Franti, M., Michael, E., Ketas, T. J., Sanders, R. W., Maddon, P. J., Olson, W. C., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.14.8812-8827.2005 · Cited by 119

Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E

Wang, S., Pal, R., Mascola, J. R., Chou, T.-H. W., Mboudjeka, I., Shen, S., Liu, Q., Whitney, S., Keen, T., Nair, B. C., et al. (2006) · Virology · doi:10.1016/j.virol.2006.02.032 · Cited by 110

In vivo Effects of Vaccination with Six-Transmembrane Epithelial Antigen of the Prostate: A Candidate Antigen for Treating Prostate Cancer

García-Hernández, M. D. L. L., Gray, A., Hubby, B., & Kast, W. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2996 · Cited by 105

Enhanced Immunogenicity of gp120 Protein When Combined with Recombinant DNA Priming To Generate Antibodies That Neutralize the JR-FL Primary Isolate of Human Immunodeficiency Virus Type 1

Wang, S., Arthos, J. A., Lawrence, J. M., Ryk, D. V., Mboudjeka, I., Shen, S., Chou, T.-H. W., Montefiori, D. C., & Lu, S. (2005) · Journal of Virology · doi:10.1128/jvi.79.12.7933-7937.2005 · Cited by 103

rBCG Induces Strong Antigen-Specific T Cell Responses in Rhesus Macaques in a Prime-Boost Setting with an Adenovirus 35 Tuberculosis Vaccine Vector

Magalhaes, I., Sizemore, D. R., Ahmed, R. K. S., Mueller, S., Wehlin, L., Scanga, C. A., Weichold, F., Schirru, G., Pau, M. G., Goudsmit, J., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003790 · Cited by 95

Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype

Pal, R., Wang, S., Kalyanaraman, V. S., Nair, B. C., Whitney, S., Keen, T., Hocker, L., Hudacik, L., Rose, N., Mboudjeka, I., et al. (2006) · Virology · doi:10.1016/j.virol.2005.12.029 · Cited by 94

Heterologous HA DNA vaccine prime—inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses

Wang, S., Parker, C., Taaffe, J. E., Solórzano, A., García‐Sastre, A., & Lu, S. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.04.073 · Cited by 91

Improved Induction of Antibodies against Key Neutralizing Epitopes by Human Immunodeficiency Virus Type 1 gp120 DNA Prime-Protein Boost Vaccination Compared to gp120 Protein-Only Vaccination

Vaine, M., Wang, S., Crooks, E. T., Jiang, P., Montefiori, D. C., Binley, J. Μ., & Lu, S. (2008) · Journal of Virology · doi:10.1128/jvi.00562-08 · Cited by 79

Priming with Plasmid DNAs Expressing Interleukin-12 and Simian Immunodeficiency Virus Gag Enhances the Immunogenicity and Efficacy of an Experimental AIDS Vaccine Based on Recombinant Vesicular Stomatitis Virus

Egan, M. A., Chong, S. Y., Megati, S., Montefiori, D. C., Rose, N. F., Boyer, J., Sidhu, M. K., Quiroz, J., Rosati, M., Schadeck, E. B., et al. (2005) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2005.21.629 · Cited by 73

Enhanced Potency of Plasmid DNA Microparticle Human Immunodeficiency Virus Vaccines in Rhesus Macaques by Using a Priming-Boosting Regimen with Recombinant Proteins

Otten, G. R., Schaefer, M. E., Doe, B., Liu, H., Srivastava, I. K., Megede, J. Z., Kazzaz, J., Lian, Y., Singh, M., Ugozzoli, M., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.13.8189-8200.2005 · Cited by 72

DNA Priming-Protein Boosting Enhances Both Antigen-Specific Antibody and Th1-Type Cellular Immune Responses in a Murine Herpes Simplex Virus-2 gD Vaccine Model

Sin, J.-I., Bagarazzi, M. L., Pachuk, C. J., & Weiner, D. B. (1999) · DNA and Cell Biology · doi:10.1089/104454999314917 · Cited by 70

Multifunctional T-Cell Characteristics Induced by a Polyvalent DNA Prime/Protein Boost Human Immunodeficiency Virus Type 1 Vaccine Regimen Given to Healthy Adults Are Dependent on the Route and Dose of Administration

Bansal, A., Jackson, B., West, K., Wang, S., Lu, S., Kennedy, J. S., & Goepfert, P. (2008) · Journal of Virology · doi:10.1128/jvi.00068-08 · Cited by 70

The prime-boost concept applied to HIV preventive vaccines.

Jl, E., & Plotkin, S. A. (1997) · PubMed · Cited by 67

Neutralizing Antibodies Against HIV-1 BRU and SF2 Isolates Generated in Mice Immunized with Recombinant Vaccinia Virus Expressing HIV-1 (BRU) Envelope Glycoproteins and Boosted with Homologous gp160

Hu, S., KLANIECKI, J., Dykers, T., Sridhar, P., & Travis, B. M. (1991) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1991.7.615 · Cited by 64

The Order of Prime-Boost Vaccination of Neonatal Calves with Mycobacterium bovis BCG and a DNA Vaccine Encoding Mycobacterial Proteins Hsp65, Hsp70, and Apa Is Not Critical for Enhancing Protection against Bovine Tuberculosis

Skinner, M. A., Wedlock, D. N., de Lisle, G. W., Cooke, M. M., Tascon, R. E., Ferraz, J. C., Lowrie, D. B., Vordermeier, H. M., Hewinson, R. G., & Buddle, B. M. (2005) · Infection and Immunity · doi:10.1128/iai.73.7.4441-4444.2005 · Cited by 64

Improved immunogenicity of a tuberculosis DNA vaccine encoding ESAT6 by DNA priming and protein boosting

Wang, Q., Sun, S., Zhenlin, H., Yin, M., Xiao, C.-J., & Zhang, J. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.03.029 · Cited by 58

Efficient induction of T helper 1 CD4+ T-cell responses to hepatitis C virus core and E2 by a DNA prime–adenovirus boost

Park, S., Yang, S.-H., Lee, C. G., Youn, J., Chang, J., & Sung, Y. C. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00499-7 · Cited by 46

Combination DNA plus protein HIV vaccines

Lu, S. (2006) · Springer Seminars in Immunopathology · doi:10.1007/s00281-006-0028-1 · Cited by 45

A Combined DNA Vaccine-Prime, BCG-Boost Strategy Results in Better Protection Against Mycobacterium bovis Challenge

Cai, H., Yu, D.-H., Hu, X.-D., Li, S. X., & Zhu, Y. (2006) · DNA and Cell Biology · doi:10.1089/dna.2006.25.438 · Cited by 40

Preexposure Efficacy of a Novel Combination DNA and Inactivated Rabies Virus Vaccine

Biswas, S., Reddy, G. S., Srinivasan, V. A., & Rangarajan, P. N. (2001) · Human Gene Therapy · doi:10.1089/104303401753153965 · Cited by 36

Augmented humoral and cellular immune responses of a hepatitis B DNA vaccine encoding HBsAg by protein boosting

He, X., Sun, S., Zhenlin, H., Jun, L., Jiang, L., Feng-juan, Z., Ya-nan, Z., & Ying-Jun, G. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.10.013 · Cited by 30

Passive immunotherapy of Bacillus anthracis pulmonary infection in mice with antisera produced by DNA immunization

Herrmann, J. E., Wang, S., Zhang, C., Panchal, R. G., Bavari, S., Lyons, C. R., Lovchik, J. A., Golding, B., Shiloach, J., & Lu, S. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.04.065 · Cited by 29

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Logunov, D. Y., Dolzhikova, I. V., Shcheblyakov, D. V., Tukhvatulin, A. I., Zubkova, O. V., Dzharullaeva, A. S., Kovyrshina, A. V., Lubenets, N. L., Grousova, D. M., Erokhova, A. S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00234-8 · Cited by 1,747

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Logunov, D. Y., Dolzhikova, I. V., Zubkova, O. V., Tukhvatulin, A. I., Shcheblyakov, D. V., Dzharullaeva, A. S., Grousova, D. M., Erokhova, A. S., Kovyrshina, A. V., Botikov, A. G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31866-3 · Cited by 1,055

Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines

Fernandes, Q., Inchakalody, V. P., Merhi, M., Mestiri, S., Taib, N., El-Ella, D. M. A., Bedhiafi, T., Raza, A., Al-Zaidan, L., Mohsen, M. O., et al. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2031274 · Cited by 466

Sputnik V COVID-19 vaccine candidate appears safe and effective

Jones, I. M., & Roy, P. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00191-4 · Cited by 378

A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development

Li, Y., Tenchov, R., Smoot, J., Liu, C., Watkins, S., & Zhou, Q. A. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00120 · Cited by 349

Prime-boost vaccine strategy against viral infections: Mechanisms and benefits

Kardani, K., Bolhassani, A., & Shahbazi, S. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.11.062 · Cited by 262

Heterologous prime boost COVID 19 vaccination

Launay, O., & Thill, P. (2022) · Infectious Diseases Now · doi:10.1016/j.idnow.2022.09.011 · Cited by 6

Heterologous Prime-Boost Vaccination in Tumor Immunotherapy

Palmowski, M. J., & Smith, C. S. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-680-5_9 · Cited by 2

Vaccination strategies, the Power of the Unmatched Double Hits

Al‐Qaisi, T. S., & Abumsimir, B. (2023) · Future Science OA · doi:10.2144/fsoa-2023-0090 · Cited by 3

Safety and Immunogenicity of Heterologous Prime-Boost Vaccinations across different Infectious Diseases: A Scoping Review ProtocolPreprint

Tina, L. O. (2026) · OSF Preprints (OSF Preprints) · doi:10.17605/osf.io/7jtme